Privia Health Group, Inc. (NASDAQ:PRVA) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 13.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 939,170 shares of the company's stock after buying an additional 114,647 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.78% of Privia Health Group worth $18,361,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in PRVA. Two Sigma Advisers LP acquired a new stake in shares of Privia Health Group in the fourth quarter valued at approximately $940,000. Two Sigma Investments LP lifted its stake in Privia Health Group by 153.9% in the 4th quarter. Two Sigma Investments LP now owns 219,839 shares of the company's stock valued at $4,298,000 after buying an additional 133,239 shares in the last quarter. Teza Capital Management LLC grew its holdings in Privia Health Group by 6.1% during the 4th quarter. Teza Capital Management LLC now owns 30,884 shares of the company's stock valued at $604,000 after buying an additional 1,777 shares during the last quarter. State of Wyoming grew its holdings in Privia Health Group by 125.0% during the 4th quarter. State of Wyoming now owns 18,227 shares of the company's stock valued at $356,000 after buying an additional 10,126 shares during the last quarter. Finally, ProShare Advisors LLC increased its position in Privia Health Group by 44.5% during the fourth quarter. ProShare Advisors LLC now owns 30,770 shares of the company's stock worth $602,000 after buying an additional 9,475 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company's stock.

Insider Buying and Selling

In other news, CFO David Mountcastle sold 5,630 shares of the business's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the completion of the sale, the chief financial officer now owns 179,676 shares in the company, valued at approximately $4,021,148.88. The trade was a 3.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Matthew Shawn Morris sold 10,309 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $240,508.97. Following the completion of the transaction, the director now owns 59,792 shares in the company, valued at $1,394,947.36. The trade was a 14.71% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 51,579 shares of company stock valued at $1,226,367. 10.70% of the stock is currently owned by company insiders.

Privia Health Group Trading Up 0.3%

Shares of PRVA traded up $0.07 during mid-day trading on Monday, reaching $22.83. The company had a trading volume of 938,228 shares, compared to its average volume of 740,286. The stock has a market cap of $2.78 billion, a price-to-earnings ratio of 228.32, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. The firm has a fifty day simple moving average of $23.34 and a 200-day simple moving average of $22.74. Privia Health Group, Inc. has a fifty-two week low of $16.37 and a fifty-two week high of $26.09.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Needham & Company LLC restated a "buy" rating and issued a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. JMP Securities restated a "market outperform" rating and issued a $29.00 target price on shares of Privia Health Group in a report on Monday, April 28th. Piper Sandler raised their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Robert W. Baird boosted their price objective on shares of Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. Finally, Truist Financial upped their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $27.77.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.